Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

未开盘 03-30 16:00:00 EDT

8.29

-0.11

-1.31%

盘后8.41

+0.12+1.45%

19:56 EDT

最高9.00	最低8.25	成交量128.03万
今开9.00	昨收8.40	日振幅8.93%
总市值2.59亿	流通市值1.30亿	总股本3,129万
成交额1,085万	换手率8.16%	流通股本1,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.29,"timestamp":1774900800000,"preClose":8.4,"halted":0,"volume":1280310,"hourTrading":{"tag":"盘后","latestPrice":8.41,"preClose":8.29,"latestTime":"19:56 EDT","volume":17939,"amount":148954.1724,"timestamp":1774915009232,"change":0.12,"changeRate":0.014475,"amplitude":0.040832},"delay":0,"changeRate":-0.013095238095238238,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"未开盘","change":-0.11,"latestTime":"03-30 16:00:00 EDT","open":9,"high":9,"low":8.25,"amount":10847583.953130001,"amplitude":0.089286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774944000000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.4,"preHourTrading":{"tag":"盘前","latestPrice":9.07,"preClose":8.4,"latestTime":"09:27 EDT","volume":6843,"amount":61711.316781,"timestamp":1774877260060,"change":0.67,"changeRate":0.079762,"amplitude":0.221429},"postHourTrading":{"tag":"盘后","latestPrice":8.41,"preClose":8.29,"latestTime":"19:56 EDT","volume":17939,"amount":148954.1724,"timestamp":1774915009232,"change":0.12,"changeRate":0.014475,"amplitude":0.040832},"volumeRatio":0.624252,"impliedVol":0.8333,"impliedVolPercentile":0.4426},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"1139966539","title":"Outlook Therapeutics完成500万美元公开发行募资","url":"https://stock-news.laohu8.com/highlight/detail?id=1139966539","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139966539?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:07","pubTimestamp":1774469224,"startTime":"0","endTime":"0","summary":"新泽西州艾斯林2026年3月25日电——专注于提升视网膜疾病治疗标准生物制药企业Outlook Therapeutics, Inc.今日宣布，已完成此前公布的2000万股普通股及配套认股权证公开发行。每份认股权证可额外认购1股普通股，发行单元定价为0.25美元。认股权证行权价每股0.25美元，即日生效，有效期五年。本次发行扣除承销费用前的总收益为500万美元。若认股权证全部以现金行权，公司有望再获约500万美元资金注入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LENZ","BK4007","TM","BK4585","03160","BK4555","BK4604","BK4099","OTLK","BK4539"],"gpt_icon":0},{"id":"1111228340","title":"Lenz Therapeutics公布2025年第四季度及全年财务业绩与近期企业动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1111228340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111228340?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:02","pubTimestamp":1774353743,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics近日披露了2025年第四季度及全年的财务数据，并同步更新了公司近期的战略进展与重要里程碑。此次公布的信息全面展现了企业在财务运营、研发推进及业务拓展方面的综合表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2620780632","title":"诺华(NVS.US)拟斥资30亿美元收购Synnovation Therapeutics乳腺癌药物资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780632","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780632?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:58","pubTimestamp":1774004312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华集团同意以最高30亿美元的价格收购Synnovation Therapeutics旗下一款实验性乳腺癌药物，以强化其肿瘤学产品管线。根据市场汇编的分析师预期，诺华目前用于治疗此类乳腺癌的药物Piqray，今年销售额预计将下滑9%，至约3.48亿美元。诺华称，该药物旨在精准靶向肿瘤细胞，同时减少对正常细胞的影响，这种策略有望\"为患者带来更好的耐受性和更持久的获益\"。截至周四，诺华股价年内累计上涨6.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","BK4578","BK4588","BK4007","BK4539","IE00BJT1NW94.SGD","LU0208291251.USD","BK4139","IE00BFTCPJ56.SGD","BK4532","LENZ","BK4585","IE0009355771.USD","LU0320765489.SGD","NVS","LU0070302665.USD","LU0211331839.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2620044915","title":"BioVie分拆的肝病药企Option Therapeutics(OPTN.US)缩减IPO规模 下调募资额20%至2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620044915?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:21","pubTimestamp":1773732080,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，从BioVie分拆出来的临床二期肝病生物技术公司Option Therapeutics缩减了其即将进行的IPO的规模。这家总部位于内华达州卡森城的公司现计划通过发行180万股、定价区间为10至12美元的方式募资2000万美元。以发行价区间中值计算，Option Therapeutics的募资额将比此前预期减少20%。该公司专注于开发治疗严重及危及生命的肝脏疾病的候选药物。Option Therapeutics目前尚未产生收入。Option Therapeutics成立于2025年，计划在纽约证券交易所美国板上市，股票代码为OPTN。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","OPTN","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2618337451","title":"Aldeyra Therapeutics, Inc.盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618337451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618337451?lang=zh_cn&edition=full","pubTime":"2026-03-12 00:08","pubTimestamp":1773245317,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日00时08分，Aldeyra Therapeutics, Inc.股票出现波动，股价快速下跌5.19%。Aldeyra Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Acurx Pharmaceuticals, Inc.、Kala Bio, Inc.、天演药业涨幅较大，Acurx Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为2240.92%、1066.56%、69.28%，振幅较大的相关个股有Acurx Pharmaceuticals, Inc.、天演药业、Kala Bio, Inc.，振幅分别为62.07%、56.62%、50.19%。Aldeyra Therapeutics, Inc.公司简介：Aldeyra Therapeutics Inc是一家生物技术公司，致力于开发和商业化下一代药物，以改善免疫介导和代谢疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312000837a461b244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312000837a461b244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","BK4007","ALDX"],"gpt_icon":0},{"id":"2618765923","title":"Silence Therapeutics Plc盘中异动 股价大涨6.06%报6.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618765923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618765923?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:14","pubTimestamp":1773238451,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日22时14分，Silence Therapeutics Plc股票出现波动，股价急速上涨6.06%。截至发稿，该股报6.65美元/股，成交量1.749万股，换手率0.04%，振幅5.26%。Silence Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.39%。Silence Therapeutics Plc公司简介：Silence Therapeutics PLCPLC是一家生物技术公司，专注于发现和开发含有短干扰核糖核酸或siRNA的新分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122141197add7f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122141197add7f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","SLN","BK4139","BK4007"],"gpt_icon":0},{"id":"2618968768","title":"Galectin Therapeutics Inc.盘中异动 下午盘急速跳水5.67%报3.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968768","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618968768?lang=zh_cn&edition=full","pubTime":"2026-03-11 02:08","pubTimestamp":1773166132,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日02时08分，Galectin Therapeutics Inc.股票出现异动，股价快速下挫5.67%。截至发稿，该股报3.16美元/股，成交量44.3595万股，换手率0.69%，振幅8.66%。Galectin Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.90%。其相关个股中，Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为1100.49%、1003.30%、702.88%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为116.47%、109.01%、60.16%。Galectin Therapeutics Inc.公司简介：Galectin Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4539","BK4139","GALT"],"gpt_icon":0},{"id":"2618608064","title":"Quince Therapeutics, Inc.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608064","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618608064?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:32","pubTimestamp":1773063134,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时32分，Quince Therapeutics, Inc.股票出现异动，股价急速下挫5.08%。Quince Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Relmada Therapeutics, Inc.、Xenon制药、Dianthus Therapeutics, Inc.涨幅较大，Relmada Therapeutics, Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为30.31%、18.75%、13.16%，振幅较大的相关个股有Aditxt, Inc.、Reviva Pharmaceuticals Holdings, Inc.、Uniqure N.V.，振幅分别为17.03%、13.72%、12.96%。Quince Therapeutics, Inc.公司简介：Quince Therapeutics Inc 是一家临床前阶段的生物制药公司，专注于推进针对衰弱和罕见疾病的精准治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921321497ab242c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921321497ab242c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","QNCX","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"1110091863","title":"Relmada Therapeutics宣布超额认购1.6亿美元私募股权融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1110091863","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110091863?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:07","pubTimestamp":1773054442,"startTime":"0","endTime":"0","summary":"佛罗里达州科勒尔盖布尔斯，2026年3月9日——临床阶段生物技术公司Relmada Therapeutics, Inc.今日宣布，已签订证券购买协议，通过非公开市场进行股权投资融资，预计将为公司带来约1.6亿美元的总收益。根据协议条款，Relmada将出售合计2947.4569万股普通股，每股作价4.75美元；同时发行421.0527万份预融资权证，每份权证定价4.749美元。Relmada作为专注于肿瘤与中枢神经系统疾病创新疗法的研发企业，其核心候选药物NDV-01和sepranolone已进入中期临床试验阶段，有望填补当前治疗领域的空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","RLMD","LENZ"],"gpt_icon":0},{"id":"2618189617","title":"炎症性疾病生物技术公司Invea Therapeutics(INAI.US)撤回3500万美元IPO计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189617","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618189617?lang=zh_cn&edition=full","pubTime":"2026-03-09 14:29","pubTimestamp":1773037756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开发炎症性疾病口服小分子药物的临床阶段生物科技公司Invea Therapeutics(INAI.US)于上周五以市场状况为由，撤回了其美股首次公开募股计划。该公司此前提交的招股书显示，拟以每股10至12美元的价格发行320万股，募资3500万美元。这家总部位于康涅狄格州吉尔福德的公司成立于2021年，原计划在纳斯达克上市，股票代码为INAI。ThinkEquity原定为该交易的独家账簿管理人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","INAI","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2618611853","title":"Lineage Cell Therapeutics, Inc.2025财年实现净利润-63.53百万美元，同比减少241.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611853","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618611853?lang=zh_cn&edition=full","pubTime":"2026-03-09 00:01","pubTimestamp":1772985680,"startTime":"0","endTime":"0","summary":"3月9日，Lineage Cell Therapeutics, Inc.公布财报，公告显示公司2025财年净利润为-63.53百万美元，同比减少241.38%；其中营业收入为14.56百万美元，同比增加53.26%，每股基本收益为-0.28美元。从资产负债表来看，Lineage Cell Therapeutics, Inc.总负债69.24百万美元，其中短期债务853000.00美元，资产负债比为0.02，流动比率为5.21。机构评级：截至2026年3月9日，当前有5家机构对Lineage Cell Therapeutics, Inc.目标价做出预测，其中目标均价为4.60美元，其中最低目标价为3.00美元，最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000152a4587951&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000152a4587951&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LINE","LENZ"],"gpt_icon":0},{"id":"2618615109","title":"Keros Therapeutics, Inc.2025财年实现净利润87.01百万美元，同比增加146.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618615109","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618615109?lang=zh_cn&edition=full","pubTime":"2026-03-09 00:00","pubTimestamp":1772985647,"startTime":"0","endTime":"0","summary":"3月9日，Keros Therapeutics, Inc.公布财报，公告显示公司2025财年净利润为87.01百万美元，同比增加146.53%；其中营业收入为2.44亿美元，同比增加6773.24%，每股基本收益为2.34美元。从资产负债表来看，Keros Therapeutics, Inc.总负债39.74百万美元，其中短期债务2.41百万美元，资产负债比为0.09，流动比率为0.16。机构评级：截至2026年3月9日，当前有6家机构对Keros Therapeutics, Inc.目标价做出预测，其中目标均价为21.83美元，其中最低目标价为16.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000105a6af58e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000105a6af58e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KROS"],"gpt_icon":0},{"id":"2617575662","title":"Relay Therapeutics, Inc.2025财年实现净利润-2.76亿美元，同比增加18.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575662","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617575662?lang=zh_cn&edition=full","pubTime":"2026-03-08 00:00","pubTimestamp":1772899221,"startTime":"0","endTime":"0","summary":"3月8日，Relay Therapeutics, Inc.公布财报，公告显示公司2025财年净利润为-2.76亿美元，同比增加18.34%；其中营业收入为15.36百万美元，同比增加53.45%，每股基本收益为-1.61美元。从资产负债表来看，Relay Therapeutics, Inc.总负债54.27百万美元，其中短期债务3.77百万美元，资产负债比为0.12，流动比率为0.23。机构评级：截至2026年3月8日，当前有10家机构对Relay Therapeutics, Inc.目标价做出预测，其中目标均价为15.80美元，其中最低目标价为13.00美元，最高目标价为19.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308000023a4568cce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308000023a4568cce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLAY","LENZ"],"gpt_icon":0},{"id":"2617583816","title":"Lineage Cell Therapeutics, Inc.盘中异动 早盘股价大涨5.43%报1.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617583816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617583816?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:31","pubTimestamp":1772807502,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日22时31分，Lineage Cell Therapeutics, Inc.股票出现异动，股价急速上涨5.43%。Lineage Cell Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.27%。其相关个股中，Day One Biopharmaceuticals, Inc.、Solid Biosciences Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Day One Biopharmaceuticals, Inc.、Quince Therapeutics, Inc.、Reviva Pharmaceuticals Holdings, Inc.较为活跃，换手率分别为26.07%、19.67%、16.48%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Contineum Therapeutics, Inc.、Cartesian Therapeutics, Inc.，振幅分别为24.36%、9.30%、7.69%。Lineage Cell Therapeutics, Inc.公司简介：Lineage Cell Therapeutics Inc是一家临床阶段的生物技术公司，专注于开发和商业化用于治疗退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306223142954392bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306223142954392bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4224","BK4539","BK4139","BK4007","LINE","LCTX","LENZ"],"gpt_icon":0},{"id":"2617180527","title":"Gain Therapeutics, Inc.盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617180527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617180527?lang=zh_cn&edition=full","pubTime":"2026-03-06 01:49","pubTimestamp":1772732944,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日01时49分，Gain Therapeutics, Inc.股票出现异动，股价快速跳水5.06%。Gain Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.11%。Gain Therapeutics, Inc.公司简介：Gain Therapeutics Inc是一家生物技术公司，开发新型小分子疗法，用于治疗多个治疗领域的疾病，包括溶酶体储存疾病、中枢神经系统疾病、代谢疾病和肿瘤疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306014904a450c0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306014904a450c0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","GANX","BK4539","LENZ"],"gpt_icon":0},{"id":"2617684440","title":"美国OTC市场Sorrento Therapeutics, Inc.盘中异动 大幅下挫10.53%报0.002美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617684440?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:46","pubTimestamp":1772721995,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时46分，美国OTC市场Sorrento Therapeutics, Inc.股票出现异动，股价大幅下跌10.53%。美国OTC市场Sorrento Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。美国OTC市场Sorrento Therapeutics, Inc.公司简介：Sorrento Therapeutics Inc是一家生物技术公司，专注于肿瘤和自身免疫/炎症疾病的新型免疫疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305224636a4504a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305224636a4504a53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SRNEQ","BK4139","SRNE","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2617543232","title":"Design Therapeutics, Inc.盘中异动 急速拉升5.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617543232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617543232?lang=zh_cn&edition=full","pubTime":"2026-03-04 23:24","pubTimestamp":1772637888,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日23时24分，Design Therapeutics, Inc.股票出现波动，股价快速拉升5.90%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304232448954303c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304232448954303c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","BK4505","DSGN","LENZ","BK4539"],"gpt_icon":0},{"id":"2617552908","title":"Maplight Therapeutics, Inc.盘中异动 股价大涨5.11%报18.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617552908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617552908?lang=zh_cn&edition=full","pubTime":"2026-03-04 03:41","pubTimestamp":1772566875,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日03时41分，Maplight Therapeutics, Inc.股票出现波动，股价急速拉升5.11%。截至发稿，该股报18.50美元/股，成交量7.8101万股，换手率0.17%，振幅7.81%。Maplight Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.80%。其相关个股中，Edesa Biotech, Inc.、Onconetix, Inc.、Hcw Biologics Inc.涨幅较大，Edesa Biotech, Inc.、Onconetix, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为306.82%、199.87%、139.79%，振幅较大的相关个股有Edesa Biotech, Inc.、Onconetix, Inc.、Yd Bio Ltd C/Wts 28/08/2030，振幅分别为76.32%、47.82%、43.99%。Maplight Therapeutics, Inc.公司简介：malight Therapeutics是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MPLT","BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2616322697","title":"Kyverna Therapeutics, Inc.盘中异动 快速跳水5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616322697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616322697?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:48","pubTimestamp":1772549307,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时48分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅下挫5.29%。截至发稿，该股报8.06美元/股，成交量3.4792万股，换手率0.06%，振幅3.52%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.35%。其相关个股中，Edesa Biotech, Inc.、Calcimedica, Inc.、Hcw Biologics Inc.涨幅较大，Adial Pharmaceuticals, Inc、Propanc Biopharma, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为116.76%、58.61%、52.81%，振幅较大的相关个股有Edesa Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Cardio Diagnostics Holdings Inc.，振幅分别为40.79%、27.40%、23.03%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","KYTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2616531388","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616531388?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:31","pubTimestamp":1772548314,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时31分，Dianthus Therapeutics, Inc.股票出现波动，股价急速下挫5.77%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.94%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供新型单克隆抗体，与现有的补体疗法相比，其选择性和效力更高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNTH","BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.2464},{"period":"1month","weight":-0.3855},{"period":"3month","weight":-0.4857},{"period":"6month","weight":-0.831},{"period":"1year","weight":-0.6767},{"period":"ytd","weight":-0.4819}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.154534},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}